{
    "clinical_study": {
        "@rank": "109131", 
        "arm_group": {
            "arm_group_label": "Metformin", 
            "arm_group_type": "Experimental", 
            "description": "7 days of pretreatment with metformin before full pharmacokinetics and other goals are investigated.\nMinimum 1 week of washout after this period. 3 weeks of pretreatment with St John's Wort and the last 7 days metformin is ingested again, and the same effect parameters as described above is performed again"
        }, 
        "brief_summary": {
            "textblock": "The goal of the study is to examine the difference of the pharmacokinetics of metformin with\n      and without a 3 weeks pretreatment of St John's Wort. Furthermore secondary objectives\n      include changes in GLP-1, C-peptide, serum-insulin and plasma-glucose during an oral glucose\n      tolerance test, changes in OCT1 mRNA in plasma and changes in leptin and lipid-profile\n      following this possible interaction."
        }, 
        "brief_title": "Interaction Between St John's Wort and Metformin?", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Type 2 Diabetes", 
            "Depression"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Depression", 
                "Depressive Disorder", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men aged 18-64 years\n\n          -  Homozygous for common genetic variants in the genes organic cation transporter 1/2\n             (OCT1/OCT2)\n\n          -  Normal values of biomarkers accounting for: Liver and kidney function, and normal\n             blood glucose\n\n        Exclusion Criteria:\n\n          -  Chronic alcohol abuse\n\n          -  Hypersensitivity to metformin or St John's Wort\n\n          -  Daily intake of drugs requiring prescription"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01726764", 
            "org_study_id": "AKF-382"
        }, 
        "intervention": [
            {
                "arm_group_label": "Metformin", 
                "intervention_name": "St John's Wort", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Metformin", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 1, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Odense", 
                    "country": "Denmark", 
                    "zip": "DK-5000"
                }, 
                "name": "Department of Clinical Pharmacology, Institute of Public Health, University of Southern Denmark"
            }
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "1", 
        "official_title": "Is There a Pharmacokinetic Interaction Between St John's Wort and Metformin?", 
        "other_outcome": {
            "description": "If possible measure the concentrations of some of the active components of St John's Wort, hypericin and hyperforin", 
            "measure": "Hypericin/hyperforin", 
            "safety_issue": "No", 
            "time_frame": "At t=0 in 2nd period"
        }, 
        "overall_official": [
            {
                "affiliation": "University of Southern Denmark", 
                "last_name": "Per Damkier, MD ph.d.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Southern Denmark", 
                "last_name": "Tore B. Stage, M.Sc. Pharm", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Southern Denmark", 
                "last_name": "Kim Br\u00f8sen, Professor, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Denmark: Danish Health and Medicines Authority", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in 0-24h AUC of metformin after 3 weeks of treatment with St John's Wort", 
            "measure": "Change in Area Under Curve (AUC) 0-24h of metformin", 
            "safety_issue": "No", 
            "time_frame": "Concentration of metformin at 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24 hours after metformin ingestion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01726764"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Southern Denmark", 
            "investigator_full_name": "Tore B. Stage", 
            "investigator_title": "M.Sc. Pharm", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Changes in: Plasma-glucose, serum-insulin, glucagon-like peptide 1 (GLP-1) and connecting-peptides (C-peptides) during the oral glucose tolerance test, measured at 0, 0.5, 1, 1.5 and 2 hours after metformin ingestion.", 
                "measure": "Oral glucose tolerance test (OGTT)", 
                "safety_issue": "No", 
                "time_frame": "During the first 2 hours of each metformin ingestion"
            }, 
            {
                "description": "Determination of other pharmacokinetic parameters of metformin such as clearance (CL), absorption fraction (F), distribution volume (V), the minimum concentration at steady state (Css,min), elimination half life (T 1/2) etc.", 
                "measure": "Pharmacokinetics of metformin", 
                "safety_issue": "No", 
                "time_frame": "Concentration of metformin at 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24 hours after metformin ingestion, which will be used to determine the pharmacokinetic parameters mentioned below"
            }, 
            {
                "description": "Changes in mRNA encoding OCT1 will be measured at 4 different time points to give an insight to the importance of St John's Wort effect on the OCT1 production", 
                "measure": "Change in messenger RiboNucleic Acid (mRNA)", 
                "safety_issue": "No", 
                "time_frame": "Will be measured 4 times: At inclusion (t=0 on that day), at t=0 in both periods and minimum 3 weeks after finalization of the study (t=0 on that day)"
            }
        ], 
        "source": "University of Southern Denmark", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Southern Denmark", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}